Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

105.93USD
20 Jul 2018
Change (% chg)

$-0.33 (-0.31%)
Prev Close
$106.26
Open
$106.33
Day's High
$108.05
Day's Low
$105.78
Volume
173,571
Avg. Vol
333,363
52-wk High
$153.80
52-wk Low
$70.78

Select another date:

Tue, May 15 2018

BRIEF-Alnylam Pharmaceuticals Says On May 12, Co's Board Expanded Size Of Board From Ten To Eleven

* ALNYLAM PHARMACEUTICALS INC SAYS ON MAY 12, CO'S BOARD EXPANDED SIZE OF BOARD FROM TEN TO ELEVEN - SEC FILING Source http://bit.ly/2KrXrlM Further company coverage:

BRIEF-Alnylam Appoints Colleen Reitan To The Board Of Directors

* ALNYLAM APPOINTS COLLEEN REITAN TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics

* ALNYLAM REPORTS PRECLINICAL DATA DEMONSTRATING CENTRAL NERVOUS SYSTEM (CNS) DELIVERY OF RNAI THERAPEUTICS

BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran

* ALNYLAM ACHIEVES ALIGNMENT WITH FDA ON ACCELERATED DEVELOPMENT PATH FOR LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran

* ALNYLAM REPORTS NEW CLINICAL RESULTS FROM THE APOLLO PHASE 3 STUDY OF PATISIRAN AT THE AMERICAN ACADEMY OF NEUROLOGY 2018 ANNUAL MEETING

BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis

* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Select another date: